Mitchell Smith
Professor of Medicine, Director of Cancer and Blood Disorders Division
GW Cancer Center, George Washington University · Washington, United States
Former Director of Lymphoid Malignancy Program at Cleveland Clinic and Fox Chase Cancer Center. Extensive clinical trial experience in lymphoma.
Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapy.
Blood advances · Mar 19, 2026
Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.
Hematology. American Society of Hematology. Education Program · Dec 5, 2025
Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma.
Nature communications · Nov 5, 2025
Copanlisib in combination with venetoclax in patients with relapsed/refractory mantle cell lymphoma.
Leukemia & lymphoma · Oct 31, 2025
NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.
Journal of the National Comprehensive Cancer Network : JNCCN · Oct 1, 2025
Translocations can drive expression changes of multiple genes in regulons covering entire chromosome arms.
Nucleic acids research · Aug 11, 2025
Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naïve or relapsed/refractory mantle cell lymphoma: phase Ib trial.
Haematologica · Mar 1, 2025
Evaluation of Bruton's Tyrosine Kinase (BTK) inhibition with alternative doses of ibrutinib in subjects with Chronic Lymphocytic Leukemia (CLL).
Cancer chemotherapy and pharmacology · Feb 28, 2025
Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis.
Blood advances · Sep 10, 2024
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL.
Blood · Sep 5, 2024
Antibrush Border Antibody Disease: A Case Series.
Kidney medicine · Jul 1, 2024
CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.
Blood advances · Jun 25, 2024
Editor's Note: Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells.
Clinical cancer research : an official journal of the American Association for Cancer Research · May 1, 2024
Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma.
Blood advances · Mar 26, 2024
Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study.
Blood advances · Mar 12, 2024
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors.
Haematologica · Jan 1, 2024